Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chordoma: early-phase trial registry
7 of 16 indexed Chordoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 7 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Chordoma: 16 US clinical trials tracked, 7 recruiting.
Chordoma is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition chordoma
OPEN 7 | RECR 44% | LATE 0 | EARLY 9 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)
Chordoma lists 7 open slots (44% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chordoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chordoma is recruiting below its size-band peers.
7 of 16 indexed trials (43.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Chordoma trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 2 of 16 trials (12.5%). 13 distinct sponsors appear on at least one study for this condition label.
-
Most Chordoma trials plan to enrol fewer than 100 people.
Median target enrolment is 38 among the 16 trials that report a genuine target (sentinel values excluded). 13 of those (81.3%) plan for fewer than 100 participants.
-
Chordoma splits between interventional and observational designs.
11 interventional and 5 observational studies make up this index (68.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Long-Term Longitudinal QoL in Patients Undergoing EEA
Ohio State University
NCT04087902
Children and Adults With Chordoma
National Cancer Institute (NCI)
NCT03910465
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
Mayo Clinic
NCT05033288
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Susan Chi, MD
NCT05407441
A Study of ERAS-601 in People With Chordoma
Memorial Sloan Kettering Cancer Center
NCT06957327
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
NCT06625190
Pembrolizumab and Pemetrexed for Progressive Chordoma
Saint John's Cancer Institute
NCT06794645
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
M.D. Anderson Cancer Center
NCT05041127
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02989636
Proton Beam Therapy for Chordoma Patients
M.D. Anderson Cancer Center
NCT00496119
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Children's Oncology Group
NCT00919269
Chordoma Family Study
National Cancer Institute (NCI)
NCT00410670
Stereotactic Body Radiotherapy for Spine Tumors
Mercy Research
NCT01347307
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
Bavarian Nordic
NCT04246671
Nilotinib With Radiation for High Risk Chordoma
Massachusetts General Hospital
NCT01407198
Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas
Massachusetts General Hospital
NCT00713037
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Chordoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chordoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chordoma page
16 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Chordoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Chordoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chordoma condition card totals 16 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.